Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Baffert, F., Regnier, C.H., De Pover, A., Pissot-Soldermann, C., Tavares, G.A., Blasco, F., Brueggen, J., Chene, P., Drueckes, P., Erdmann, D., Furet, P., Gerspacher, M., Lang, M., Ledieu, D., Nolan, L., Ruetz, S., Trappe, J., Vangrevelinghe, E., Wartmann, M., Wyder, L., Hofmann, F., Radimerski, T.(2010) Mol Cancer Ther 9: 1945-1955
- PubMed: 20587663 
- DOI: https://doi.org/10.1158/1535-7163.MCT-10-0053
- Primary Citation of Related Structures:  
3KRR - PubMed Abstract: 
The recent discovery of an acquired activating point mutation in JAK2, substituting valine at amino acid position 617 for phenylalanine, has greatly improved our understanding of the molecular mechanism underlying chronic myeloproliferative neoplasms. Strikingly, the JAK2(V617F) mutation is found in nearly all patients suffering from polycythemia vera and in roughly every second patient suffering from essential thrombocythemia and primary myelofibrosis ...